Abstract:
The present disclosure provides compounds of Formula (I) and (II), which may be R0CK2 inhibitors. The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, and methods of treating or preventing diseases and disorders associated with R0CK2 (e.g., fibrotic disease, autoimmune disease, inflammatory-fibrotic condition, inflammatory condition, edema, ophthalmic disease, cardiovascular disease, central nervous system disorder, cancer) by administering to a subject in need thereof the compounds or pharmaceutical compositions.
Abstract:
Disclosed systems and methods relate to predicting the relative representation of genomic variants in an edited cell population, based on the editing cassette design representation in an editing cassette design library used to generate the edited cell population. A library of editing cassette designs is generated, and a feature vector, or sequence embedding, is developed for each design using natural language processing techniques. The feature vector may be based upon sequence attributes and editing kinetics of each cassette design as well as attributes that describe the library context. Features may include sequence embeddings generated from a neural network, linguistic-type distances, and statistical distance summaries thereof. The feature vectors are classified using one or more machine learning models, and the classified feature vectors are used to predict the representation of each design an edited cell population.
Abstract:
Methods, compositions, kits, and systems are provided for identifying regions of genomic DNA bound to a protein. The methods may include contacting genomic DNA with an adenine methyltransferase (A-MTase), where the A-MTase causes methylation of adenine residues in regions of the genomic DNA not bound to a protein; and conducting single molecule long read sequencing of the contacted genomic DNA to detect locations in the genomic DNA lacking methylated adenine residues to identify regions of genomic DNA bound to a protein. The bound regions may be nucleosome positions and the methods may determinenucleosome positions in genomic DNA. Also provided are methods for visualization of regions of chromatin not bound to a protein and spatially available as a substrate for an adenine methyltransferase (A-MTase) in a cell by visualizing location of methylated adenines after contacting the cells with the A-MTase.
Abstract:
The present invention generally relates to systems and methods for high throughput selection. In one aspect, cells are contained within gel droplets, and the cells may interact with the gel droplet in some manner, e.g., to form the gel and/or to degrade the gel. The interaction of cells with the gel droplet may result in some cells being contained within gel droplets and other cells not being contained within gel droplets, which may form the basis by which the cells are sorted. Such cells can be relatively rapidly sorted, e.g., on the basis of size, for example, using filtration, centrifugation, or other similar techniques. In some cases, unlike sorting techniques which can only sort one entity, such as droplets, at a time, such techniques can allow for more than one entity (and in some cases, relatively large numbers of entities) to be simultaneously sorted, dramatically increasing throughput.
Abstract:
The invention provides methods of increasing immune response by inducing iron-dependent cellular disassembly. The increase in immune response may be used, for example, for treatment of infection or cancer. The invention also provides screening assays for identification of compounds that induce iron-dependent cellular disassembly and are also immunostimulatory agents. The invention further provides methods for identifying immunostimulatory agents produced by cells undergoing iron-dependent cellular disassembly.
Abstract:
The invention provides methods of increasing immune response by inducing iron- dependent cellular disassembly. The increase in immune response may be used, for example, for treatment of infection or cancer. The invention also provides screening assays for identification of compounds that induce iron-dependent cellular disassembly and are also immuno stimulatory agents. The invention further provides methods for identifying immuno stimulatory agents produced by cells undergoing iron-dependent cellular disassembly.
Abstract:
The present disclosure relates to novel macrocyclic compounds and libraries thereof that are useful as research tools for drug discovery efforts. This disclosure also relates to methods of preparing these compounds and libraries and methods of using these libraries, such as in high throughput screening. In particular, these libraries are useful for evaluation of bioactivity at existing and newly identified pharmacologically relevant targets, including G protein-coupled receptors, nuclear receptors, enzymes, ion channels, transporters, transcription factors, protein-protein interactions and nucleic acid-protein interactions. As such, these libraries can be applied to the search for new pharmaceutical agents for the treatment and prevention of a range of medical conditions.
Abstract:
The invention relates to improved methods of treating a cancer in a patient in need thereof using combination drug regimens that can improve therapeutic efficacy of kinase inhibitor(s). Such combination drug regimens may also reduce side effects of kinase inhibitor(s) and/or prevent or reduce cancer resistance to the kinase inhibitor(s).
Abstract:
The present disclosure relates to proteomic biomarkers of spontaneous preterm birth, proteomic biomarkers of term birth, and methods of use thereof. In particular, the present disclosure provides tools for determining whether a pregnant subject is at an increased risk for premature delivery, as well as tools for decreasing a pregnant subject's risk for premature delivery.
Abstract:
This invention relates to a gene encoding a GPR113, wherein GPR113 is a taste receptor polypeptide which detects fat tastants. In one embodiment the invention relates to the use of the GPR113 receptor in screening assays for identifying fat, lipid and fatty acid taste modulators or compounds that mimic fat taste. In another embodiment the invention relates a method for reducing dietary preferences for fat containing foods, comprising administering to a subject a compounds which modulates GPR113. In another embodiment the invention relates to comestibles containing an amount of a compound that specifically binds or modulates GPR113 activity, e.g. a GPR113 enhancer or GPR113 blocker, in an amount sufficient to modulate or mimic fat or lipid taste or to affect fat or lipid metabolism.